Posted on

Lamar Odom To Speak At Meet Delic In Las Vegas

Lamar Odom To Speak At Meet Delic In Las Vegas

NBA superstar to speak at Meet Delic in Las Vegas about his embrace of psychedelic treatments and screen the film which chronicles his near-fatal overdose and recovery with psychedelics. He joins world’s leading experts, scientists, and health & wellness advocates to gather for a two-day immersive edutainment experience at AREA15 from November 6 – 7, 2021.

Vancouver, BC, September 28, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (original source), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on November 7. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers, earning him NBA championships in 2009 and 2010. He joined LeBron James, Allen Iverson, Tim Duncan and Dwayne Wade as members of the goldwinning U.S. men’s basketball team at the 2004 Athens Olympics.

In 2015 Odom was hospitalized in Las Vegas after a near-death overdose that resulted in multiple seizures, strokes and a coma. The upcoming documentary Lamar Odom Reborn chronicles his life, from past traumas and struggles with anxiety and substance abuse to his recovery and healing through psychedelic treatments, meditation and breathwork. Odom’s keynote “Fireside Chat: Lamar Odom & Zappy Zapolin: Reborn” will reunite him with the documentary’s director for an intimate discussion of his healing journey with psychedelic medicine and a preview of the film.

“We’re so honored Lamar will be sharing his personal story of healing with all of us at Meet Delic,” said Jackee Stang, co-founder of Delic. “He has shown tremendous courage facing his past traumas and addiction, and his openness to exploring psychedelic treatments is inspiring. We hope his story will open the hearts and minds of more people so we can truly address the growing mental health crisis we’re facing.”

Meet Delic is committed to bringing awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community by reframing the psychedelic conversation. The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo. The full lineup of keynote speakers and panelists can be found here.

The twenty hours of panels and keynotes will include an array of topics such as “Why Are Psychedelics Medicine?”, “How Big Money is (Already) Playing Psychedelics,” “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “Microdosing,” “Psychedelic Activism,” “Aphrodisiacs and Psychedelics: A History of Medicine for Love”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.                                                                                                       

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement. 

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forwardlooking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forwardlooking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com  

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, mjaramillo@labeltheagency.com

Posted on

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Delic Closes C$7.0 Million Private Placement With U.S. Institutional Investor to Fuel Growth of Largest National Presence

Funding to Open New Psychedelic Wellness Clinic Locations, Adding to Leading Footprint

Not for dissemination in the United States or to U.S. newswire services

VANCOUVER, BC September 27, 2021 – Delic Holdings Corp. (“Delic” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has closed its previously announced sale to a single institutional investor for gross proceeds of approximately C$7.0 million in a private placement in the United States (the “Private Placement“).

Pursuant to the Private Placement, the Company issued ‎9,000,000 units of the Company (the “Units“) at a price of C$0.285 per Unit and 15,561,404 pre-funded ‎units of the Company (the “Pre-Funded Units“) at a price of C$0.2849. Each Unit is comprised of one subordinate voting share (a “SV Share“) and one subordinate voting share purchase warrant (a “Warrant“). Each Warrant entitles the holder thereof to purchase one ‎additional SV Share (a “Warrant Share“) at an exercise price of C$0.38 per Warrant Share, subject to ‎‎adjustment, at any time on or prior to 5:00 p.m. ‎‎(Eastern Time) on September 28, 2026. Each Pre-Funded Unit is comprised of one pre-funded subordinate voting share purchase warrant ‎‎(a “Pre-Funded Warrant“) and one Warrant. Each ‎Pre-Funded Warrant entitles the holder thereof to purchase one SV Share (a “Pre-Funded Warrant Share“) at ‎an exercise price of C$0.0001 per Pre-Funded Warrant Share and shall terminate upon exercise in full of ‎the Pre-Funded Warrants. ‎‎

H.C. Wainwright & Co. (“H.C. Wainwright“) acted as the exclusive placement agent for the Private Placement.

H.C. Wainwright received (i) a cash commission of $560,000.01 (equal to 8.0% of the gross proceeds of the Private Placement) and (ii) 1,964,912 compensation warrants (the “Agent Warrants“). Each Agent Warrant entitles the holder thereof to purchase one SV Share at an exercise price of C$0.38 per SV Share at any time on or prior to 5:00 pm (Eastern Time) on September 28, 2026.

The SV Shares, Pre-Funded Warrants and Warrants issued under the Private Placement were qualified by way of a prospectus supplement dated September 24, 2021 under the Company’s short form base shelf prospectus dated September 14, 2021 (the “Prospectus Supplement“) which was filed in the Province of British Columbia. In the United States, the SV Shares, Pre-Funded Warrants and Warrants and the shares issuable upon the exercise of the Pre-Funded Warrants and Warrants were offered on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), and certain other jurisdictions in accordance with applicable securities laws.

The Company intends to use the net proceeds of the Private Placement for expanding clinic foot print, operating costs and acquisitions.

The Private Placement is subject to customary notices and deliveries to the Canadian Securities Exchange.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in Canada in connection with the Private Placement.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities being offered have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of U.S. Persons (within the meaning of Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Delic Corp, Inc.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: use of the net proceeds of the Private Placement; and the receipt of all necessary regulatory and stock exchange approvals for the Private Placement.

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to:

the potential impact of the closing of the Private Placement on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; and compliance ‎with extensive government regulation.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Media Relations Contact

Rich Rodriguez

rich@deliccorp.com

Investor Relations Contact

Daniel Southan-Dwyer

dsd@deliccorp.com

Posted on

Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience

Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience

Meet Delic Announces Full Event, Speaker & Entertainment Lineup for Two-Day Immersive Edutainment Experience

Thought Leaders, Entrepreneurs, Medical Experts and Entertainment Headliners include Duncan Trussell, Shane Mauss, Alyson Charles, Dr. Carl Hart, Ifetayo Harvey, Aubrey Marcus…and a surprise special guest speaker

Vancouver, BC, September 23, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today released the full lineup of thought leaders, entrepreneurs, medical experts and entertainers taking part in the two-day premier psychedelics event. The experiential event will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

The list of thought leaders who will keynote the two-day event taking place from November 6th7th, 2021, at AREA15, an immersive and experiential venue in Las Vegas, includes:

  • Duncan Trussell, stand-up comedian, podcaster and actor, host of The Duncan Trussell Family Hour
  • Jason Silva, Venezuelan-American filmmaker, philosopher, television personality, and public speaker
  • Aubrey Marcus, founder of Onnit, podcast host and best-selling author
  • Alyson Charles, former TV/radio host and athlete turned author, spiritual teacher, medium and shaman
  • Dr. Carl Hart, Ziff Professor at Columbia University, former chair of the Department of Psychology and best-selling author
  • Chris Ryan, PhD, NYT bestselling author and featured speaker at influential conferences such as TED, SXSW, and a frequent guest on The Joe Rogan Experience
  • Ifetayo Harvey, Founder and board president of the People of Color Psychedelic Collective; activist, writer and social media manager at Caring Across Generations
  • George Goldsmith, CEO and founder of COMPASS Pathways and an entrepreneur
  • Ekaterina Malievskaia, MD, Co-founder and Chief Innovation Officer for COMPASS
  • Luke Storey, Motivational speaker, podcaster, writer, meditation and metaphysics teacher, and lifestyle design expert
  • Dr. Molly Maloof, Founder of Adamo Bioscience and a lecturer within the Wellness Department of the Medical School at Stanford University
  • Ben Westhoff, Award-winning investigative reporter who writes about culture, drugs, and poverty
  • Brittany Hoogenboom, Owner and founder of Synergy Soul, a mind, body, soul, & business brand, and an intuitive business coach
  • Dr. Dave Rabin, MD, PhD, Neuroscientist, board-certified psychiatrist, health tech entrepreneur and inventor. Co-founder & Chief Innovation Officer at Apollo Neuroscience
  • Laura Dawn, Msc., Host of The Psychedelic Leadership Podcast, and a microdosing mentor for executives, who has led transformational retreats for over 10 years
  • Shane Mauss, Stand-up comedian, adventurer, podcaster, psychonaut and science enthusiast
  • Kyle Bergquist, Founder of Healing Our Heroes, co-founder of Serving Impact, author and documentary filmmaker
  • Jesse Gould, Psychedelic ranger and founder of Heroic Hearts Project
  • Zappy Zapolin, Futurist, award-winning filmmaker, and psychedelic concierge to the stars
  • Clara Burtenshaw, Partner and investor at Neo Kuma Ventures, the first psychedelics focused venture capital fund in Europe

The following business leaders, scientists and health & wellness advocates will come together for a series of thought-provoking panels on making psychedelics accessible to the masses:

Business Panelists

  • Martin Tobias, Founder of Incisive Ventures, investor and entrepreneur
  • Matt Stang, Pioneer for the cannabis industry in the U.S. and CEO of Delic Corp
  • Mark Goldfogel, Serial entrepreneur and co-founder of KERN, the first cannabis compliance company on NASDAQ
  • Sara Kennedy, Marketing entrepreneur focusing in plant-based particles
  • Joshua White, Co-founder and Executive Director of Fireside Project
  • Mitchell Gomez, Executive Director at DanceSafe
  • Sam Chapman, Executive Director at Healing Advocacy Fund
  • Dr. Markus Roggen, President and Chief Scientific Officer of Delic Labs
  • Donald Gauvreau, Founder, CEO and Chairman at Conscious Mind Labs
  • Ronan Levy, Entrepreneur, founder and Executive Chairman of Field Trip Health
  • Barbara Branaman, Co-Founder and CEO of BioReset Group, Co-Host of the Clarity Cafe Podcast, doctor of Medical Qigong, yoga and meditation teacher
  • Paul Rosen, Founder, CEO and Chairman of Tidal Royalty Corporation
  • Gary Smith, Co-founder and President of Arizona Cannabis Bar Association; author and psychedelic lawyer
  • Kraig Fox, Advisor and entertainment industry superpower ● Nanea Reeves, CEO and co-founder at TRIPP, Inc.
  • Sashko Despotovski, Investor and board member at Delic Corp
  • Dina Burkitbayeva, Founder of PsyMed Ventures, psychedelics biotech investor and entrepreneur
  • Matt Zemon, Chief Strategy Officer and co-founder at Psychable ● Jennifer Pereira, CEO of Bloom Fund and angel investor
  • Kathryn Fantauzzi, CEO and co-founder of Apollo Neuroscience
  • Hanifa Nayo Washington, Sacred activist, co-founder and cultivator of Beloved Community of Fireside Project
  • Lauren Mendelsohn, Esq., Senior associate attorney, Law Offices of Omar Figueroa
  • Sonia Weiss Pick, Co-founder and Managing Director at WPSS Investments
  • Lisa Dannen, MA, Director of Marketing & Communications, Maya Health
  • Dr. Jeff Chen, MD/MBA, Impact entrepreneur, scientist, and storyteller operating at the convergence of culture, science, and business to heal the body, mind, and planet. Cofounder & CEO of Radical Science
  • Ifetayo Harvey will also be taking part in a business panel

Wellness Panelists

  • Adam Bramlage, Founder and CEO ofFlow State, where he works one-on-one with clients to optimize their microdosing experience
  • Phoebe McPherson, Co-founder of the Hearthstone Collective, a mushroom company on a mission to help others heal with plant medicines
  • Jemie Sae Koo, CEO of Psychable.com, an online community dedicated to connecting those interested in legally exploring psychedelic-assisted therapy with practitioners who can support them
  • Victor Mifsud, Creator of the personal feature-length documentary “My Neuroplastic Adventure,” taking viewers from the cutting edge of neuroscience to ancient tribal healing medicines
  • Dr. Stephanie Coleman, MD/MPH, Holistic and psychedelic medicine physician, educator, and entrepreneur
  • Dr. Devon Christie, MD, Clinical instructor with the UBC Department of Medicine and has a focused practice in chronic pain management
  • Will Siu, MD, DPhil, Advisor to Bexson Biomedical and People Science has been trained by MAPS to provide MDMA-assisted therapy
  • Craig Salerno, LAC/LPC, Licensed addiction counselor and licensed professional counselor
  • Sashi Gerzon-Rose, LPC, Psychotherapist, yoga and meditation teacher, and ordained monk in the White Plum lineage of Zen Buddhism
  • David Feifel, MD/PhD, Professor Emeritus of Psychiatry at University of California San Diego and a pioneer in treating mental illness
  • Spencer Hawkswell, CEO at TheraPsilLobbyist, believes responsible drug policy requires effective organization and leadership
  • Deanne Adamson, Founder and President of Being True To You and an addiction specialist
  • Sam Ko, MD/MBA, Founder and Medical Director of Reset Ketamine
  • Lauren Taus, LCSW, Psychotherapist with a specialty in psychedelic assisted therapies
  • Amber Amendola, Psychotherapist with 10 years of health and wellness experience, focused on the healing potential of non-ordinary states of consciousness
  • Robbie Bent, Thought leader in the mental health space building a global community to improve mental health in an accessible way
  • Dr. Matt Cook, President and founder of BioReset™ Medical and Medical Advisor of Bioreset Network.
  • Dr. Harry McIlroy, MD, Family physician, licensed acupuncturist, functional medicine practitioner, osteopath, nutritionist, certified Ashtanga yoga teacher
  • Florencia Bollini, Named “The Corporate Shaman” by Forbes Magazine, one of the pioneering practitioners of the plant medicine world
  • Dr. Dave Rabin, MD, PhD, Laura Dawn, Msc., Jennifer Pereira and Dr. Jeff Chen, MD/MBA, will also be joining the wellness panels

Entertainment

Attendees will be treated to an exciting mix of live music, visual art and dancers on both evenings.

  • The greatest hits of psychedelia past, present and future will be played during The Psyche-Delic Experience, an after-party performance on Saturday, November 6, featuring DJ David Starfire and VJ Jonathan Singer, including a tribute to the Legends of psychedelia featuring the music of The Beatles, Jefferson Airplane, Jimi Hendrix, The Grateful Dead with “appearances” by Alan Watts, Timothy Leary, Terrence McKenna and Ram Das
  • A special tribute performance of Pink Floyd’s “Set The Controls For The Heart Of The Sun” created as a 360 VR immersive film
  • Futuristic psychedelia dance and techno themes featuring the music of Tipper, Sphongle, Desert Dwellers, Bedouin, and all original music by David Starfire with dancers and performance artists
  • MINDCHATTER, a project by singer, songwriter, and producer Bryce Connolly, will provide live music on Sunday, November 6. His complex sound displays influences from electronic, indie, singer-songwriter and hip-hop
  • Dance performances by Little Miss Nasty and visual art by Scott Hedstrom

The twenty hours of panels and keynotes will include an array of topics such as “Psychedelics and the Search for Truth”, “Why Are Psychedelics Medicine?”, “The Shortcomings of Wellness”, “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Psychedelics and Sobriety: The Next Frontier in Recovery“, “Microdosing,” “Psychedelic Activism,” “Digital Dosing: Technology & Innovation Powering Psychedelics”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

           ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement. 

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forwardlooking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forwardlooking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com  

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com

Posted on

Delic Announces C$7.0 Million Private Placement With Institutional Investor

Delic Announces C$7.0 Million Private Placement With Institutional Investor

VANCOUVER, BC September 22, 2021 – Delic Holdings Corp. (“Delic” or the “Company“) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) is pleased to announce that it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately C$7.0 million in a private placement in the United States (the “Private Placement“). Pursuant to the Private Placement, the Company will issue 24,561,404 subordinate voting shares (each, a “SV Share“) (or SV Share equivalents) and warrants to purchase up to 24,561,404 SV Shares (each, a “Warrant“) at a purchase price of C$0.285 per SV Share and associated Warrant. Each Warrant entitles the holder to purchase one SV Share at an exercise price of C$0.38 for five years from the issuance date.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the Private Placement.

The SV Shares and Warrants to be issued under the Private Placement will be qualified by way of a prospectus supplement under the Company’s short form base shelf prospectus dated September 14, 2021 (the “Prospectus Supplement”) which will be filed in the Province of British Columbia. In the United States, the SV Shares, Warrants and the SV Shares issuable upon the exercise of the Warrants will be offered on a private placement basis pursuant to exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and certain other jurisdictions in accordance with applicable securities laws.

The net proceeds of the Private Placement will be used by the Company for expanding clinic foot print, operating costs and acquisitions.

Closing of the Private Placement is expected to occur on or about September 27, 2021, subject to satisfaction of customary closing conditions.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in Canada in connection with the Private Placement.

This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States. The securities being offered have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of U.S. Persons (within the meaning of Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Delic Corp, Inc.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable ‎Canadian securities ‎legislation and may also contain statements that may constitute “forward-looking ‎statements” within the meaning of ‎the safe harbor provisions of the United States Private Securities ‎Litigation Reform Act of 1995. Such forward-looking ‎information and forward-looking statements are not ‎representative of historical facts or information or current ‎condition, but instead represent only the ‎Company’s beliefs regarding future events, plans or objectives, many of ‎which, by their nature, are ‎inherently uncertain and outside of Delic’s control. Generally, such forward-looking ‎information or ‎forward-looking statements can be identified by the use of forward-looking terminology such as ‎‎”plans”, ‎‎”expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, ‎‎‎”anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may ‎contain ‎statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be ‎taken”, “will continue”, ‎‎”will occur” or “will be achieved”. The forward-looking information and forward-‎looking statements contained herein ‎may include, but are not limited to: Placement; and the receipt of all necessary approvals for the Private Placement the completion of the Private Placement; the amount and use of the net proceeds of the Private Placement; the anticipated closing date of the Private Placement; the qualification of the SV Shares and Warrants issued under the Private Placement and the filing of ‎the Prospectus Supplement in British Columbia; the satisfaction of the closing conditions for the Private.

By identifying such information and statements in this manner, Delic is alerting the reader that ‎such ‎information and statements are subject to known and unknown risks, uncertainties and other factors ‎that may cause ‎the actual results, level of activity, performance or achievements of Delic to be ‎materially different from those ‎expressed or implied by such information and statements. Such risks and other factors may include, but are not limited to: risks and uncertainties relating to the Private Placement not closing as planned or at all or on terms and conditions set forth in the securities purchase agreement; direct and indirect material adverse effects from the COVID-19 pandemic; inability to obtain future financing on suitable terms; failure to obtain required regulatory and other approvals; risks inherent in the psychedelic treatment sector; changes in applicable laws and regulations; and failure to comply with applicable laws and regulations.

In addition, in ‎connection with the forward-looking ‎information and forward-looking statements contained in this press ‎release, Delic has made certain ‎assumptions. These assumptions include, but are not limited to:

assumptions as to the time required to complete matters related to the Private Placement; the ability to complete the Private Placement; ‎the ability of the parties to ‎obtain, in a timely manner, the requisite regulatory, corporate and other third party approvals and the satisfaction of ‎other conditions to the ‎Private Placement on the proposed terms; the potential impact of the announcement or consummation of the Private Placement on ‎relationships, ‎including with regulatory bodies, employees, suppliers, customers and competitors; ‎changes in general economic, ‎business and political conditions, including changes in the financial ‎markets; changes in applicable laws; and compliance ‎with extensive government regulation.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions ‎underlying the ‎forward-looking information or statements prove incorrect, actual results may vary ‎materially from those described ‎herein as intended, planned, anticipated, believed, estimated or ‎expected.‎

Although Delic believes that the assumptions and factors used in preparing, and the expectations ‎contained ‎in, the forward-looking information and statements are reasonable, undue reliance should not ‎be placed on such ‎information and statements, and no assurance or guarantee can be given that such ‎forward-looking information and ‎statements will prove to be accurate, as actual results and future events ‎could differ materially from those anticipated ‎in such information and statements. The forward-looking ‎information and forward-looking statements contained in this ‎press release are made as of the date of ‎this press release, and Delic does not undertake to update any ‎forward-looking information ‎and/or forward-looking statements that are contained or referenced herein, except in ‎accordance with ‎applicable securities laws. All subsequent written and oral forward- looking information and ‎statements ‎attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this ‎‎notice.‎

Media Relations Contact

Rich Rodriguez

rich@deliccorp.com

Investor Relations Contact

Daniel Southan-Dwyer

dsd@deliccorp.com

Posted on

Delic Announces Alyson Charles, Shaman and Best-Selling Author to Keynote at The World’s Premiere Psychedelic and Wellness Event: Meet Delic, November 6-7, 2021

Delic Announces Alyson Charles, Shaman and Best-Selling Author to Keynote at The World’s Premiere Psychedelic and Wellness Event: Meet Delic, November 6-7, 2021

Vancouver, BC, September 1st, 2021 – Delic Holdings Corp. (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, today announced that Alyson Charles will serve as one of the keynote speakers at Meet Delic the world’s premiere psychedelic and wellness edutainment event catering to both curious newcomers, business and thought leaders.

Renowned Shaman, Best-Selling Author of ‘Animal Power,’ and Host of Ceremony Circle Podcast, Alyson Charles, went from being a national champion athlete, top-rated radio host and national daytime television talk show host, to aligning with her calling as a Shaman after a traumatic moment provided her awakening.  Since then, her ability to share ancient sacred wisdom and divine energy has allowed her to be a powerful catalyst for change that ignites  a global phenomenon. Forbes has called her both “a leading Shaman for expanding others into their full gifts and power” and “a full-fledged guide into your psyche,” Oprah Magazine named Alyson’s guided Shamanic journey “a top meditation to try,” Huffington Post championed her as “a top limit-breaking female founder,” Dazed Magazine named her “one of the top seven wellness accounts on Instagram” and Marie Claire Magazine selected her as the cover story and “the next big thing.”

“With so many people feeling a pull toward psychedelics, having education-based events with diversity and unity like Meet Delic are more important than ever,” said Alyson Charles. “I’m so excited to be able to share my deep reverence, teachings and personal experiences of my devotion and calling to Shamanism.”

Charles’ keynote appearance, Surrender & Integration: Creating Soul and Plant Spirit Alignment to Master the Journey, will discuss connecting to one’s full Divine power and spiritual gifts. Her presentation will cover how working with psychedelics is not something to be forced or taken lightly, but rather a potential process to open oneself up to with sacredness and to heed only when a genuine call to enters in. It’s a deep journey of learning to trust in oneself and Divine timing.

“Alyson brings an incredibly powerful and personal story to the journey we all must go through to connect with ourselves and how psychedelics can be powerful tools along the way,” said Delic co-founder, Jackee Stang. “I’m excited for her to share more with our diverse audience of psychonauts, business leaders, entrepreneurs and those brand new to psychedelic wellness.”

Meet Delic will feature dancers, music, 3D mapping, new technologies and research, thought-provoking presentations and the world’s largest psychedelic business expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Media Inquiries: Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com